, Tanja Kosak Soklic 2
, Aleksandra Aleksic 3
, Gabriela Kopacheva-Barsova 4
, Aneta V. Peric 5
2Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Slovenia
3Clinical Centre of the Republic of Srpska, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
4ENT University Clinic, University Campus “St. Mother Theresa”, Skopje, Republic of North Macedonia
5Institute for Pharmacy, Military Medical Academy, Faculty of Medicine, University of Defence, Crnotravska, Belgrade, Serbia
Abstract
The clinical pattern of rhinosinusitis is based on key symptoms, such as nasal obstruction/congestion, nasal secretion with postnasal discharge, facial pain with pressure, and impaired sense of smell. Acute rhinosinusitis is a viral infection commonly caused by impaired paranasal sinus aeration and drainage and can progress to bacterial superinfection. Chronic rhinosinusitis is an inflammatory disease of the sinonasal mucosa with symptoms persisting for more than 12 weeks. This paper aimed to summarize and update the literature related to the use of herbal product Myrtol® standardized in the treatment of acute and chronic rhinosinusitis. Earlier investigations have demonstrated that Myrtol® standardized has strong secretolytic, secretomotoric, anti-inflammatory, antioxidative, and antimicrobial effects. Therefore, this study reviewed randomized studies related to its use in the treatment of upper-airway inflammations and discussed the mechanisms of action of this herbal drug on infected nasal and paranasal sinuses mucosa.